Chronic itch is one of the most prominent clinical characteristics of diverse systematic
diseases. It is a devastating sensation in pathological diseases. Despite its importance …

Background Spesolimab is an anti-interleukin-36 receptor monoclonal antibody approved to
treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and safety …

Introduction Significant advances in psoriasis treatment have taken place since the
introduction of biologics. Tumor necrosis factor inhibitors were the first class of biologics …

Background Drug survival, defined as the length of time from initiation to discontinuation of a
given therapy, allows comparisons between drugs, helps to predict patient's likelihood of …

Introduction Guselkumab safety and efficacy profiles in psoriasis have been showed by
VOYAGE (1 and 2) trials. Although trial results have been already previously confirmed by …

Background Clinical trials have shown promising results for interleukin-23 inhibitors in the
treatment of psoriasis. The drugs have been used in clinical practice since 2017. Objective …

Abstract Background and Objective The most recently approved biologics for moderate-to-
severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently …

Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of
Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year …

Background Real‐world studies on the use of biologics in psoriasis (Pso) are increasing, but
still scarce. Trough concentrations (C ts) of interleukin‐17 inhibitors (IL‐17i) seem promising …

Introduction There is limited and conflicting evidence over the real-world drug survival of
secukinumab (SEC) in patients with psoriasis, especially in the long term. Our objective was …